-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42

Benzinga·01/09/2026 15:55:56
Listen to the news
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.